Ridinilazole

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, November 17, 2022
Marketing, COVID-19, EPIX, Doctor of Philosophy, University of Turin, GSK, Clinical Colorectal Cancer, Alessandra, Food, University, Team, Amgen, Knowledge, Patient, MD, Security (finance), Cesano, Food and Drug Administration Amendments Act of 2007, Ridinilazole, Cancer, Self-signed certificate, Biogen, Risk, Panitumumab, Prostate cancer, Quality of life, SMMT, CMO, Coronavirus, Clinical trial, Medical imaging, Pharmaceutical industry

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.
  • Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs, stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • Dr. Cesano currently serves on the board of Puma Biotechnology Inc. (NASDAQ: PBYI), a clinical stage oncology company focused on solid tumors.
  • Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

Retrieved on: 
Thursday, October 13, 2022
Infection, Private Securities Litigation Reform Act, Food and Drug Administration Amendments Act of 2007, Susceptibility, NASDAQ, CDI, Pharmacist, Nasdaq, Treatment, Next Stage with You, Society of Infectious Diseases Pharmacists, Journal, Commensalism, Infectious Diseases Society of America, Vancomycin, Safety, Poster, Quality of life, Randomness, SMMT, Knowledge, Company, Marketing, Summit, PIDS, GLOBE, Clinical trial, The Journal of Infectious Diseases, Ridinilazole, Research, Security (finance), Giovanni, Trial of the century, U.S. Securities and Exchange Commission, IDSA, Diarrhea, Risk, Clostridioides difficile (bacteria), Patient, Clostridioides difficile infection, Coronavirus, Food, Efficacy, Society, Recurrence, COVID-19, Epidemiology, Pharmaceutical industry, Vaccine, Medical device, Clostridium, Clostridioides, DRS

Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.

Key Points: 
  • Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.
  • In the Ri-CoDIFy study, ridinilazole resulted in a meaningful reduction in the rate of recurrence of C. diff.
  • infection (8.1% vs 17.3%) and achieved a numerically higher sustained clinical response1 rate (73.0% vs 70.7%) than vancomycin.
  • We are pleased to inform that the results of our clinical study validated the assertions of Drs.

Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

Retrieved on: 
Monday, October 3, 2022
Virobay, Ridinilazole, Inflammation, BTK, GLOBE, Doctor of Philosophy, Stanford University School of Medicine, NASDAQ, Risk, Research, Knowledge, Clinical trial, Genomics, Drug discovery, Food, Private Securities Litigation Reform Act, CEO, Health, Hoffmann-La Roche, COVID-19, Goal, Coronavirus, University, U.S. Securities and Exchange Commission, Team, Therapy, Quality of life, Nasdaq, Autoimmune disease, Executive, Leadership, Security (finance), Patient, Hematological Cancer Research Investment and Education Act, Trauma, Celera Corporation, Food and Drug Administration Amendments Act of 2007, Character, Board of directors, Biochemistry, SMMT, Board, Marketing, Company, Medical device, Pharmaceutical industry, Management, Safety, Pharmacyclics

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD,has been appointed to its Board of Directors, effective immediately.
  • He has over 30 years of experience in the biopharmaceutical industry from executive positions to research and scientific leadership primarily focusing in the areas of oncology, inflammation, and autoimmune disease.
  • He is the co-founder of CuraSen Therapeutics, Inc. where he was previously the Executive Chairman and currently serves as an advisor.
  • Dr. Booth currently serves on the board of Thryv Therapeutics Inc.; he previously served on the boards of Pharmacyclics, Inc., and CymaBay Inc.

Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, CEO, GLOBE, Food and Drug Administration Amendments Act of 2007, SEC, Clinical trial, Sale, Security (finance), Marketing, COVID-19, Company, Risk, Coronavirus, NASDAQ, SMMT, Ridinilazole, Form 4, Overalls, Food, Health, Pharmaceutical industry

Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, "we," or the Company) today announced the successful closing of its fully-subscribed $100 million rights offering.

Key Points: 
  • Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, "we," or the Company) today announced the successful closing of its fully-subscribed $100 million rights offering.
  • The rights offering resulted in the sale of approximately 103 million shares of the Companys common stock, par value $0.01 at a price of $0.97 per share.
  • The Company received aggregate gross proceeds from the rights offering of $100 million; expenses associated with the offering are estimated to be approximately $100 thousand, yielding net proceeds of roughly $99.9 million from the offering.
  • After giving effect to the rights offering, Summit has approximately 201 million shares of common stock issued and outstanding.

Summit Therapeutics’ Rights Offering Nearing Expiration Date

Retrieved on: 
Tuesday, August 2, 2022
Private Securities Litigation Reform Act, Company, U.S. Securities and Exchange Commission, Food, Risk, Clinical trial, Subscription business model, Marketing, Food and Drug Administration Amendments Act of 2007, Security (finance), Ridinilazole, Coronavirus, COVID-19, Mail order, Pharmaceutical industry

Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ridinilazole.

Key Points: 
  • Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ridinilazole.
  • Accordingly, readers should not place undue reliance on forward-looking statements or information.
  • In addition, any forward-looking statements included in this press release represent the Companys views only as of the date of this release and should not be relied upon as representing the Companys views as of any subsequent date.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President

Retrieved on: 
Tuesday, July 26, 2022
Private Securities Litigation Reform Act, Magic, Nasdaq, Sale, Knowledge, United, GLOBE, Ernst, Anti-globalization movement, U.S. Securities and Exchange Commission, Food, Coos, Woman, AbbVie, Research, Risk, Associate, Louis Pasteur University, Marketing, SMMT, COVID-19, NASDAQ, Quality of life, Clinical trial, MBA, Infection, Company, Security (finance), Science, Patient, Overalls, Industry, Robert Maki, DDS, Growth, Schiller International University, Food and Drug Administration Amendments Act of 2007, Ridinilazole, Coronavirus, Management, Film, Pharmaceutical industry, Pharmacyclics

Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA,has been appointed as Co-Chief Executive Officer & President, effective immediately.

Key Points: 
  • Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA,has been appointed as Co-Chief Executive Officer & President, effective immediately.
  • Maky defines what it means to be a great leader, said Robert W. Duggan, Executive Chairman and Chief Executive Officer of Summit.
  • Prior to joining Summit, Dr. Zanganeh founded MakyZanganeh and Associates in 2015, and from 2008 to 2015, she held multiple leadership positions at Pharmacyclics,Inc., culminating in her role as Chief Operating Officer.
  • I am truly honored to be elevated to the Co-CEO role at Summit, stated Dr. Zanganeh.

Summit Therapeutics Provides Update on Ridinilazole

Retrieved on: 
Thursday, July 14, 2022
Knowledge, Ridinilazole, Clinical trial, Marketing, Security (finance), U.S. Securities and Exchange Commission, NASDAQ, Development, Type, US Foods, Office of Inspector General, U.S. Department of Health and Human Services, Company, Private Securities Litigation Reform Act, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, NCT, Food and Drug Administration Amendments Act of 2007, Human services, Patient, BARDA, Society, Infection, Food, Clostridioides difficile infection, GLOBE, COVID-19, IDSA, Infectious Diseases Society of America, Nasdaq, Risk, Assistant, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Pharmacist, PIDS, Society of Infectious Diseases Pharmacists, SMMT, Coronavirus, FDA, Quality of life, CA, Vancomycin, CDI, Summit, Pharmaceutical industry

Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, "we," or the Company) today provided an update with respect to the clinical development of ridinilazole, its lead Phase III product candidate for the treatment of patients with Clostridioides difficile infection (C. diff.

Key Points: 
  • Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, "we," or the Company) today provided an update with respect to the clinical development of ridinilazole, its lead Phase III product candidate for the treatment of patients with Clostridioides difficile infection (C. diff.
  • This week, Summit and the US Food & Drug Administration (the FDA) held a Type C meeting during which Summit discussed certain data from the Ri-CoDIFy Phase III clinical trial with the agency.
  • The FDA and Summit discussed a possible pathway in which to advance ridinilazole forward with the goal of achieving marketing authorization.
  • Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position.

Summit Therapeutics Announces $100 Million Rights Offering

Retrieved on: 
Wednesday, June 22, 2022
Nasdaq, SMMT, Form S-3, Security (finance), Ridinilazole, COVID-19, Risk, Private Securities Litigation Reform Act, Common stock, Summit, Prospectus, Company, Knowledge, U.S. Securities and Exchange Commission, Director, Date, Clinical trial, Marketing, NASDAQ, CA, Quality of life, Sale, SEC, Food, Board, Coronavirus, Form, Food and Drug Administration Amendments Act of 2007, GLOBE, Common, Pharmaceutical industry

Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $100 million, less expenses related to the rights offering.

Key Points: 
  • Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $100 million, less expenses related to the rights offering.
  • The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional shares of Common Stock that remain unsubscribed at the expiration of the offering.
  • The availability of the over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents.
  • The rights offering will be made pursuant to the Companys shelf registration statement on Form S-3, which became effective on October 15, 2020, and a prospectus supplement containing the detailed terms of the rights offering to be filed with the SEC.

Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting

Retrieved on: 
Friday, June 3, 2022
CA, Coronavirus, Company, Marketing, Knowledge, Food, SMMT, Ridinilazole, Security (finance), Food and Drug Administration Amendments Act of 2007, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Therapy, Risk, GLOBE, COVID-19, Quality of life, NASDAQ, Clinical trial, Summit, Nasdaq, Pharmaceutical industry

Menlo Park, CA, June 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Companys Annual Shareholders Meeting, which will now be held virtually on Thursday, June 16, 2022, at 1:00 pm Eastern Time, one day later than previously planned.

Key Points: 
  • Menlo Park, CA, June 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Companys Annual Shareholders Meeting, which will now be held virtually on Thursday, June 16, 2022, at 1:00 pm Eastern Time, one day later than previously planned.
  • As a reminder, in order to vote and/or submit questions during our Annual Shareholders Meeting, attendees must log into the virtual meeting with their unique control number provided with their 2022 Summit Therapeutics proxy statement and annual meeting information.
  • This information was provided to shareholders as of our record date of April 26, 2022, either through a physical mailing or through shareholders brokerage firms in which their shares are held.
  • Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer

Retrieved on: 
Wednesday, June 1, 2022
Coronavirus, CFO, Company, Marketing, CDNA, Knowledge, Food, SMMT, South African Institute of Chartered Accountants, Ridinilazole, Security (finance), Food and Drug Administration Amendments Act of 2007, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Agilent Technologies, Risk, GLOBE, Technology, Health, COVID-19, Quality of life, NASDAQ, Clinical trial, Nasdaq, Information technology, Institute, Pharmaceutical industry, Risk management, Management

Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingrahas been appointed as Chief Financial Officer, effective immediately.

Key Points: 
  • Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingrahas been appointed as Chief Financial Officer, effective immediately.
  • We are in a pivotal time for Team Summit as we seek to expand our portfolio of pipeline assets through potential collaborations and possible acquisitions, said Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • We are truly pleased to welcome Ankur to Team Summit.
  • I am excited to join Team Summit and its impressive leadership team, stated Mr. Dhingra.